Rubius therapeutics, inc. (RUBY)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Sep'17Jun'17
Operating expenses:
Research and development

127,734

112,419

98,458

79,291

63,134

51,769

41,356

31,814

0

0

0

General and administrative

56,311

57,182

54,837

53,076

48,332

39,894

33,160

24,181

0

0

0

Total operating expenses

184,045

169,601

153,295

132,367

111,466

91,663

74,516

55,995

0

0

0

Loss from operations

-184,045

-169,601

-153,295

-132,367

-111,466

-91,663

-74,516

-55,995

0

0

0

Other income (expense):
Interest income

0

-

-

-

0

-

-

-

-

-

-

Interest expense

2,992

2,590

2,162

1,414

964

464

349

334

0

0

0

Change in fair value of preferred stock warrant liability

-

-

-

-

-

2,187

2,246

2,313

0

0

0

Other income (expense), net

0

-

-

-

0

-

-

-

-

-

-

Interest income and other income, net

-

-

9,288

8,691

-

-

3,180

1,519

0

0

0

Total other income (expense), net

4,682

6,143

7,126

6,851

4,101

2,468

585

-1,128

0

0

0

Net loss

-179,363

-163,458

-146,169

-125,516

-107,365

-89,195

-73,931

-57,123

0

0

0

Accretion of Series A redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

-

0

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

0

0

Net loss per share, basic and diluted

-0.60

-0.57

-0.59

-0.50

-0.42

2.30

-0.42

-2.43

-1.72

-1.48

-1.25

Weighted average common shares outstanding, basic and diluted

80,271

79,699

79,115

78,396

77,544

77,748

62,311

8,727

8,355

8,078

7,866

Comprehensive loss:
Net loss

-179,363

-163,458

-146,169

-125,516

-107,365

-89,195

-73,931

-57,123

0

0

0

Other comprehensive income (loss):
Unrealized gains (losses) on investments, net of tax of $0

450

104

185

317

126

-29

0

0

0

-

-

Comprehensive loss

-178,913

-163,354

-145,984

-125,199

-107,239

-89,224

-73,950

-57,150

0

0

0